Next Article in Journal
Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults
Next Article in Special Issue
Nanotechnology and Drug Delivery: An Update in Oncology
Previous Article in Journal
The Pharmacokinetics and Pharmacodynamics of Iron Preparations
Previous Article in Special Issue
Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats
Pharmaceutics 2011, 3(1), 34-52; doi:10.3390/pharmaceutics3010034

Nano Delivers Big: Designing Molecular Missiles for Cancer Therapeutics

1, 2, 3,4,5, 2, 1 and 1,*
Received: 3 December 2010 / Revised: 6 January 2011 / Accepted: 11 January 2011 / Published: 13 January 2011
(This article belongs to the Special Issue Nanotechnology in Drug Delivery)
View Full-Text   |   Download PDF [480 KB, uploaded 13 January 2011]   |   Browse Figures


Current first-line treatments for most cancers feature a short-list of highly potent and often target-blind interventions, including chemotherapy, radiation, and surgical excision. These treatments wreak considerable havoc upon non-cancerous tissue and organs, resulting in deleterious and sometimes fatal side effects for the patient. In response, this past decade has witnessed the robust emergence of nanoparticles and, more relevantly, nanoparticle drug delivery systems (DDS), widely touted as the panacea of cancer therapeutics. While not a cure, nanoparticle DDS can successfully negotiate the clinical payoff between drug dosage and side effects by encompassing target-specific drug delivery strategies. The expanding library of nanoparticles includes lipoproteins, liposomes, dendrimers, polymers, metal and metal oxide nano-spheres and -rods, and carbon nanotubes, so do the modes of delivery. Importantly, however, the pharmaco-dynamics and –kinetics of these nano-complexes remain an urgent issue and a serious bottleneck in the transition from bench to bedside. This review addresses the rise of nanoparticle DDS platforms for cancer and explores concepts of gene/drug delivery and cytotoxicity in pre-clinical and clinical contexts.
Keywords: nano-material; cancer; drug delivery; nano-toxicity; carbon nanotube, siRNA; gene delivery nano-material; cancer; drug delivery; nano-toxicity; carbon nanotube, siRNA; gene delivery
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Patel, S.; Bhirde, A.A.; Rusling, J.F.; Chen, X.; Gutkind, J.S.; Patel, V. Nano Delivers Big: Designing Molecular Missiles for Cancer Therapeutics. Pharmaceutics 2011, 3, 34-52.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert